New wonder treatment

Israel’s VBL Therapeutics has developed VB-201 – the first of a new class of oral anti-inflammatories called Lecinoxoids. VB-201 has the potential to treat immune-inflammatory diseases such as Psoriasis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis and more. The US FDA has also granted fast-track designation for VB-111, which treats GBM – an aggressive form of brain cancer.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *